Apotex Ruxolitinib FDA Approval Date
Apotex's ruxolitinib cream 1.5%, a generic version of Incyte's Opzelura, received FDA approval on September 20, 2024. This approval allows marketing of the topical JAK inhibitor for treating mild to moderate atopic dermatitis in non-immunocompromised patients aged 12 and older.[1][2]
Why This Approval Matters for Patients
The approval provides a lower-cost alternative to the branded Opzelura, which launched in 2021 at around $2,000 per tube. Generic entry could reduce out-of-pocket costs, though actual pricing depends on pharmacy negotiations and insurance coverage.[3]
When Did the Brand Patent Expire?
Opzelura's key composition-of-matter patent (U.S. Patent No. 8,158,616) expires in 2027, but Apotex gained approval via a Paragraph IV challenge, settling litigation with Incyte. This allows earlier market entry despite ongoing exclusivity until October 2025.[2][4]
DrugPatentWatch.com tracks ruxolitinib patents and generics; see their ruxolitinib profile for expiration timelines and ANDA details.[4]
How Does Apotex's Version Compare to Opzelura?
Bioequivalent to the reference product, with identical strength (1.5% cream) and indications. No head-to-head trials, but FDA deemed it interchangeable based on pharmacokinetic and clinical data.[1]
Are Other Ruxolitinib Generics Approved?
Apotex is the first for the topical cream. Oral ruxolitinib (Jakafi/Incyte-Novartis) has generics approved since February 2023 from Sandoz and others, but topical remains limited.[5]
Launch Timeline and Availability
Apotex plans U.S. launch in Q1 2025, post-exclusivity. Shortages of Opzelura have driven demand for alternatives.[2]
Sources
[1]: FDA Approval Letter for Apotex Ruxolitinib Cream
[2]: FDA Orange Book Entry for ANDA 217869
[3]: GoodRx Opzelura Pricing
[4]: DrugPatentWatch: Opzelura Patents
[5]: FDA Jakafi Generic Approvals